Universität zu Köln

Stirrup, Oliver, Sterne, Jonathan, Dunn, David T., Grabmeier-Pfistershammer, Katharina, Papastamopoulos, Vasileios, Vandenhende, Marie-Anne, Wit, Ferdinand, Porter, Kholoud, Gunsenheimer-Bartmeyer, Barbara, Jarrin, Inma, Garcia, Federico ORCID: 0000-0001-7611-781X, Faetkenheuer, Gerd, Obel, Niels, Schultze, Anna, Antinori, Andrea, Ceccherini-Silberstein, Francesca, Mussini, Cristina, Chene, Genevieve, Neesgaard, Bastian, Castagna, Antonella, Kouyos, Roger, De Wit, Stephane, Sonnerbor, Anders, Sabin, Caroline, Merino, Dolores, Barger, Diana and Phillips, Andrew (2019). Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1. Aids, 33 (4). S. 745 - 752. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1473-5571

Full text not available from this repository.

Abstract

Objectives: Evaluate long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz+tenofovir disoproxil fumarate+emtricitabine/lamivudine (EFV+TDF+FTC/3TC), and compare these according to patient characteristics. Methods: PLWHIV enrolled in the Collaboration of Observational HIV Epidemiological Research Europe cohort collaboration, who started first-line EFV+TDF+FTC/3TC at age at least 16 years and had viral suppression (<200 copies/ml) within 9 months were included. Rates of virological failure (>= 200 copies/ml) and (complete) treatment interruption were estimated according to years since initial suppression. We used Poisson regression to examine associations of baseline characteristics with rates of virological failure or treatment interruption. Results: Among 19 527 eligible PLWHIV with median (interquartile range) follow-up 3.7 (2.0-5.6) years after initial viral suppression, the estimated rate of the combined incidence of virological failure or treatment interruption fell from 9.0/100 person-years in the first year to less than 4/100 person-years beyond 3 years from suppression; considering only those remaining on EFV+TDF+FTC/3TC, the combined rate dropped from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3 years. PLWHIV with injecting drug-related or heterosexual transmission were at higher risk of virological failure or treatment interruption, as were those of Black ethnicity. PLWHIV aged less than 35 years were at higher risk of virological failure and treatment interruption. Conclusion: PLWHIV starting first-line EFV+TDF+FTC/3TC had low rates of virological failure and treatment interruption up to 10 years from initial suppression. Demographic characteristics can be used to identify subpopulations with higher risks of these outcomes. Copyright (C) 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Stirrup, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Sterne, Jonathan UNSPECIFIED UNSPECIFIED UNSPECIFIED Dunn, David T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Grabmeier-Pfistershammer, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Papastamopoulos, Vasileios UNSPECIFIED UNSPECIFIED UNSPECIFIED Vandenhende, Marie-Anne UNSPECIFIED UNSPECIFIED UNSPECIFIED Wit, Ferdinand UNSPECIFIED UNSPECIFIED UNSPECIFIED Porter, Kholoud UNSPECIFIED UNSPECIFIED UNSPECIFIED Gunsenheimer-Bartmeyer, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Jarrin, Inma UNSPECIFIED UNSPECIFIED UNSPECIFIED Garcia, Federico UNSPECIFIED orcid.org/0000-0001-7611-781X UNSPECIFIED Faetkenheuer, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Obel, Niels UNSPECIFIED UNSPECIFIED UNSPECIFIED Schultze, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Antinori, Andrea UNSPECIFIED UNSPECIFIED UNSPECIFIED Ceccherini-Silberstein, Francesca UNSPECIFIED UNSPECIFIED UNSPECIFIED Mussini, Cristina UNSPECIFIED UNSPECIFIED UNSPECIFIED Chene, Genevieve UNSPECIFIED UNSPECIFIED UNSPECIFIED Neesgaard, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Castagna, Antonella UNSPECIFIED UNSPECIFIED UNSPECIFIED Kouyos, Roger UNSPECIFIED UNSPECIFIED UNSPECIFIED De Wit, Stephane UNSPECIFIED UNSPECIFIED UNSPECIFIED Sonnerbor, Anders UNSPECIFIED UNSPECIFIED UNSPECIFIED Sabin, Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Merino, Dolores UNSPECIFIED UNSPECIFIED UNSPECIFIED Barger, Diana UNSPECIFIED UNSPECIFIED UNSPECIFIED Phillips, Andrew UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-153640
DOI:	10.1097/QAD.0000000000002126
Journal or Publication Title:	Aids
Volume:	33
Number:	4
Page Range:	S. 745 - 752
Date:	2019
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1473-5571
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTIRETROVIRAL THERAPY; VIRAL LOAD; DURABILITY; INFECTION; EFFICACY; FAILURE Multiple languages Immunology; Infectious Diseases; Virology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15364